14,15-Epoxyeicosa-5(Z)-Enoic-mSI: A 14,15- and 5,6-EET antagonist in bovine coronary arteries

Kathryn M. Gauthier, Setti G. Jagadeesh, J R Falck, William B. Campbell

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Endothelium-dependent hyperpolarizations and relaxation of vascular smooth muscle induced by acetylcholine and bradykinin are mediated by endothelium-derived hyperpolarizing factors (EDHFs). In bovine coronary arteries, arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), function as EDHFs. The 14,15-EET analog 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI) was synthesized and tested for agonist and antagonist activity. In U46619-preconstricted bovine coronary arterial rings, 14,15-, 11,12-, 8,9-, and 5,6-EET induced maximal concentration-related relaxation averaging 75% to 87% at 10 μmol/L, whereas, 14,15-EEZE-mSI induced maximal relaxation averaging only 7%. 14,15-EEZE-mSI (10 μmol/L) preincubation inhibited relaxation to 14,15- and 5,6- EET but not 11,12- or 8,9- EET. 14,15-EEZE-mSI also inhibited indomethacin-resistant relaxation to arachidonic acid and indomethacin-resistant and L-nitroarginine-resistant relaxation to bradykinin and methacholine. It did not alter the relaxation to sodium nitroprusside, iloprost, or the K+ channel openers bimakalim or NS1619. In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, 14,15-EEZE-mSI (100 nmol/L) blocked the 14,15-EET-induced (100 nmol/L) activation of large-conductance, calcium-activated K+ channels. Mass spectrometric analysis of rat renal cortical microsomes incubated with arachidonic acid showed that 14,15-EEZE-mSI (10 μmol/L) increased EET concentrations while decreasing the concentrations of the corresponding dihydroxyeicosatrienoic acids. Therefore, 14,15-EEZE-mSI inhibits relaxation to 5,6- and 14,15- EET and the K+ channel activation by 14,15-EET. It also inhibits the EDHF component of bradykinin-induced, methacholine-induced, and arachidonic acid-induced relaxation. These results suggest that 14,15- or 5,6 -EET act as an EDHF in bovine coronary arteries.

Original languageEnglish (US)
Pages (from-to)555-561
Number of pages7
JournalHypertension
Volume42
Issue number4 I
DOIs
StatePublished - Oct 1 2003

Fingerprint

Coronary Vessels
Endothelium
Arachidonic Acid
Bradykinin
Methacholine Chloride
Indomethacin
Iloprost
Calcium-Activated Potassium Channels
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Acids
5,6-epoxy-8,11,14-eicosatrienoic acid
14,14-epoxyeicosa-5-enoic methylsulfonylimide
Nitroarginine
Nitroprusside
Microsomes
Vascular Smooth Muscle
Acetylcholine
Smooth Muscle Myocytes
Kidney
14,15-epoxy-5,8,11-eicosatrienoic acid

Keywords

  • Acetylcholine
  • Arachidonic acids
  • Bradykinin
  • Endothelium-derived factors
  • Vasodilation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

14,15-Epoxyeicosa-5(Z)-Enoic-mSI : A 14,15- and 5,6-EET antagonist in bovine coronary arteries. / Gauthier, Kathryn M.; Jagadeesh, Setti G.; Falck, J R; Campbell, William B.

In: Hypertension, Vol. 42, No. 4 I, 01.10.2003, p. 555-561.

Research output: Contribution to journalArticle

Gauthier, Kathryn M. ; Jagadeesh, Setti G. ; Falck, J R ; Campbell, William B. / 14,15-Epoxyeicosa-5(Z)-Enoic-mSI : A 14,15- and 5,6-EET antagonist in bovine coronary arteries. In: Hypertension. 2003 ; Vol. 42, No. 4 I. pp. 555-561.
@article{e132299da4a84d74ad1e64c8b368aa3e,
title = "14,15-Epoxyeicosa-5(Z)-Enoic-mSI: A 14,15- and 5,6-EET antagonist in bovine coronary arteries",
abstract = "Endothelium-dependent hyperpolarizations and relaxation of vascular smooth muscle induced by acetylcholine and bradykinin are mediated by endothelium-derived hyperpolarizing factors (EDHFs). In bovine coronary arteries, arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), function as EDHFs. The 14,15-EET analog 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI) was synthesized and tested for agonist and antagonist activity. In U46619-preconstricted bovine coronary arterial rings, 14,15-, 11,12-, 8,9-, and 5,6-EET induced maximal concentration-related relaxation averaging 75{\%} to 87{\%} at 10 μmol/L, whereas, 14,15-EEZE-mSI induced maximal relaxation averaging only 7{\%}. 14,15-EEZE-mSI (10 μmol/L) preincubation inhibited relaxation to 14,15- and 5,6- EET but not 11,12- or 8,9- EET. 14,15-EEZE-mSI also inhibited indomethacin-resistant relaxation to arachidonic acid and indomethacin-resistant and L-nitroarginine-resistant relaxation to bradykinin and methacholine. It did not alter the relaxation to sodium nitroprusside, iloprost, or the K+ channel openers bimakalim or NS1619. In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, 14,15-EEZE-mSI (100 nmol/L) blocked the 14,15-EET-induced (100 nmol/L) activation of large-conductance, calcium-activated K+ channels. Mass spectrometric analysis of rat renal cortical microsomes incubated with arachidonic acid showed that 14,15-EEZE-mSI (10 μmol/L) increased EET concentrations while decreasing the concentrations of the corresponding dihydroxyeicosatrienoic acids. Therefore, 14,15-EEZE-mSI inhibits relaxation to 5,6- and 14,15- EET and the K+ channel activation by 14,15-EET. It also inhibits the EDHF component of bradykinin-induced, methacholine-induced, and arachidonic acid-induced relaxation. These results suggest that 14,15- or 5,6 -EET act as an EDHF in bovine coronary arteries.",
keywords = "Acetylcholine, Arachidonic acids, Bradykinin, Endothelium-derived factors, Vasodilation",
author = "Gauthier, {Kathryn M.} and Jagadeesh, {Setti G.} and Falck, {J R} and Campbell, {William B.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1161/01.HYP.0000091265.94045.C7",
language = "English (US)",
volume = "42",
pages = "555--561",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4 I",

}

TY - JOUR

T1 - 14,15-Epoxyeicosa-5(Z)-Enoic-mSI

T2 - A 14,15- and 5,6-EET antagonist in bovine coronary arteries

AU - Gauthier, Kathryn M.

AU - Jagadeesh, Setti G.

AU - Falck, J R

AU - Campbell, William B.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Endothelium-dependent hyperpolarizations and relaxation of vascular smooth muscle induced by acetylcholine and bradykinin are mediated by endothelium-derived hyperpolarizing factors (EDHFs). In bovine coronary arteries, arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), function as EDHFs. The 14,15-EET analog 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI) was synthesized and tested for agonist and antagonist activity. In U46619-preconstricted bovine coronary arterial rings, 14,15-, 11,12-, 8,9-, and 5,6-EET induced maximal concentration-related relaxation averaging 75% to 87% at 10 μmol/L, whereas, 14,15-EEZE-mSI induced maximal relaxation averaging only 7%. 14,15-EEZE-mSI (10 μmol/L) preincubation inhibited relaxation to 14,15- and 5,6- EET but not 11,12- or 8,9- EET. 14,15-EEZE-mSI also inhibited indomethacin-resistant relaxation to arachidonic acid and indomethacin-resistant and L-nitroarginine-resistant relaxation to bradykinin and methacholine. It did not alter the relaxation to sodium nitroprusside, iloprost, or the K+ channel openers bimakalim or NS1619. In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, 14,15-EEZE-mSI (100 nmol/L) blocked the 14,15-EET-induced (100 nmol/L) activation of large-conductance, calcium-activated K+ channels. Mass spectrometric analysis of rat renal cortical microsomes incubated with arachidonic acid showed that 14,15-EEZE-mSI (10 μmol/L) increased EET concentrations while decreasing the concentrations of the corresponding dihydroxyeicosatrienoic acids. Therefore, 14,15-EEZE-mSI inhibits relaxation to 5,6- and 14,15- EET and the K+ channel activation by 14,15-EET. It also inhibits the EDHF component of bradykinin-induced, methacholine-induced, and arachidonic acid-induced relaxation. These results suggest that 14,15- or 5,6 -EET act as an EDHF in bovine coronary arteries.

AB - Endothelium-dependent hyperpolarizations and relaxation of vascular smooth muscle induced by acetylcholine and bradykinin are mediated by endothelium-derived hyperpolarizing factors (EDHFs). In bovine coronary arteries, arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs), function as EDHFs. The 14,15-EET analog 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI) was synthesized and tested for agonist and antagonist activity. In U46619-preconstricted bovine coronary arterial rings, 14,15-, 11,12-, 8,9-, and 5,6-EET induced maximal concentration-related relaxation averaging 75% to 87% at 10 μmol/L, whereas, 14,15-EEZE-mSI induced maximal relaxation averaging only 7%. 14,15-EEZE-mSI (10 μmol/L) preincubation inhibited relaxation to 14,15- and 5,6- EET but not 11,12- or 8,9- EET. 14,15-EEZE-mSI also inhibited indomethacin-resistant relaxation to arachidonic acid and indomethacin-resistant and L-nitroarginine-resistant relaxation to bradykinin and methacholine. It did not alter the relaxation to sodium nitroprusside, iloprost, or the K+ channel openers bimakalim or NS1619. In cell-attached patches of isolated bovine coronary arterial smooth muscle cells, 14,15-EEZE-mSI (100 nmol/L) blocked the 14,15-EET-induced (100 nmol/L) activation of large-conductance, calcium-activated K+ channels. Mass spectrometric analysis of rat renal cortical microsomes incubated with arachidonic acid showed that 14,15-EEZE-mSI (10 μmol/L) increased EET concentrations while decreasing the concentrations of the corresponding dihydroxyeicosatrienoic acids. Therefore, 14,15-EEZE-mSI inhibits relaxation to 5,6- and 14,15- EET and the K+ channel activation by 14,15-EET. It also inhibits the EDHF component of bradykinin-induced, methacholine-induced, and arachidonic acid-induced relaxation. These results suggest that 14,15- or 5,6 -EET act as an EDHF in bovine coronary arteries.

KW - Acetylcholine

KW - Arachidonic acids

KW - Bradykinin

KW - Endothelium-derived factors

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=0141962643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141962643&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000091265.94045.C7

DO - 10.1161/01.HYP.0000091265.94045.C7

M3 - Article

C2 - 12953017

AN - SCOPUS:0141962643

VL - 42

SP - 555

EP - 561

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4 I

ER -